MPLW515L mutation in acute megakaryoblastic leukaemia

Leukemia. 2009 May;23(5):852-5. doi: 10.1038/leu.2008.371. Epub 2009 Feb 5.

Abstract

The thrombopoietin receptor gene (MPL) is expressed in megakaryocytes and exhibits the gain of function point mutation W515K/L in approximately 5% of patients with primary myelofibrosis/idiopathic myelofibrosis (PMF) representing one subtype of the chronic myeloproliferative disorders (myeloproliferative neoplasm). A series of primary and secondary acute myeloid leukaemias (AML) with megakaryoblastic phenotype and myelofibrosis unrelated to PMF (n=12) was analysed for the MPL(W515K/L) mutation by pyrosequencing. In three cases (25%), MPL(W515L) was found and in two of these a combination with trisomy 21 or the Philadelphia chromosome occurred. None of the secondary AML cases evolving from pre-existing PMF showed MPL(W515K/L) (n=4). We conclude that MPL(W515L) occurs in a considerable proportion of acute megakaryoblastic leukaemias with myelofibrosis unrelated to PMF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Blast Crisis
  • Bone Marrow Cells
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Janus Kinase 2 / genetics
  • Lasers
  • Leukemia, Megakaryoblastic, Acute / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Microdissection
  • Middle Aged
  • Mutation / genetics*
  • Primary Myelofibrosis / genetics*
  • Receptors, Thrombopoietin / genetics*

Substances

  • Receptors, Thrombopoietin
  • MPL protein, human
  • JAK2 protein, human
  • Janus Kinase 2